{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:44:45Z","timestamp":1768959885211,"version":"3.49.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.coph.2022.102292","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T18:38:49Z","timestamp":1665427129000},"page":"102292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis"],"prefix":"10.1016","volume":"67","author":[{"given":"Christine P.","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102292_sref1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4081\/reumatismo.2012.66","article-title":"Epidemiology of psoriatic arthritis","volume":"64","author":"Catanoso","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.coph.2022.102292_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib121","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib122","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib123","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09546630310013360","article-title":"Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis","volume":"14","author":"Weisman","year":"2003","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.coph.2022.102292_bib124","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib8","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coph.2022.102292_bib9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2022.102292_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2022.102292_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","article-title":"Angiogenesis drives psoriasis pathogenesis","volume":"90","author":"Heidenreich","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.coph.2022.102292_sref12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/09546634.2019.1605142","article-title":"Psoriatic arthritis for dermatologists","volume":"31","author":"Gottlieb","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.coph.2022.102292_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102292_bib14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2340\/00015555-1833","article-title":"Current concepts in psoriatic arthritis: pathogenesis and management","volume":"94","author":"de Vlam","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2022.102292_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"de Korte","year":"2004","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.coph.2022.102292_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","article-title":"Determinants of quality of life in patients with psoriasis: a study from the US population","volume":"51","author":"Gelfand","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","article-title":"Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective","volume":"54","author":"Mease","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2022.102292_bib19","first-page":"119","article-title":"Psoriasis and comorbidities: links and risks","volume":"7","author":"Ni","year":"2014","journal-title":"Clin Cosmet Invest Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A\u00a0global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib129","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib130","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib36","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib133","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib43","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102292_bib52","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib53","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib55","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib75","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib71","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib136","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A\u00a0prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib72","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib79","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib138","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib86","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib80","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib82","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib81","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib90","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib94","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib103","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib35","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib104","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.61.4.298","article-title":"Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors","volume":"61","author":"Mease","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.jidsymp.5650029","article-title":"Tumor necrosis factor blockade: mechanism of action","volume":"12","author":"Gottlieb","year":"2007","journal-title":"J\u00a0Invest Dermatol Symp Proc"},{"key":"10.1016\/j.coph.2022.102292_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib26","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib29","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/247553030713a00104","article-title":"Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials","volume":"13","author":"Reich","year":"2007","journal-title":"Psoriasis Forum"},{"key":"10.1016\/j.coph.2022.102292_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coph.2022.102292_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_sref38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","article-title":"Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States","volume":"8","author":"Bergman","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.coph.2022.102292_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab pegol: a review in moderate to severe plaque psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.coph.2022.102292_bib44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.coph.2022.102292_bib46","article-title":"Risk of hospitalized serious infection after initiating ustekinumab or other biologics for psoriasis or psoriatic arthritis","author":"Jin","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coph.2022.102292_sref47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5114\/ada.2019.89507","article-title":"Antidrug antibody formation during tumor necrosis factor alpha inhibitor treatment of severe psoriatic patients in the real-life practice","volume":"36","author":"Herszenyi","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.coph.2022.102292_bib49","author":"Food and Drug Adminsitration"},{"key":"10.1016\/j.coph.2022.102292_bib50","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib51","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"mAbs"},{"key":"10.1016\/j.coph.2022.102292_bib54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102292_bib56","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102292_bib59","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.coph.2022.102292_bib60","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coph.2022.102292_bib61","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib62","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib63","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib65","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib67","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A\u00a0head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib68","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A\u00a0head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_sref74","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.coph.2022.102292_bib76","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102292_bib77","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib83","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib84","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2021-eular.398","article-title":"AB0524 efficacy of guselkumab across basdai components in treating axial-related symptoms of psoriatic arthritis: results from two phase 3, randomized","volume":"80","author":"Behrens","year":"2021","journal-title":"PLACEBO-CONTROLLED STUDIESAnnals of the Rheumatic Diseases"},{"key":"10.1016\/j.coph.2022.102292_bib85","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib88","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.coph.2022.102292_bib92","first-page":"31","article-title":"Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives","volume":"8","author":"Noisette","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.coph.2022.102292_bib96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib97","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib98","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >\/=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib99","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102292_bib101","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/acr2.11156","article-title":"Long-term safety and tolerability of apremilast versus placebo in psoriatic arthritis: a pooled safety analysis of three phase III, randomized, controlled trials","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.coph.2022.102292_bib102","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coph.2022.102292_bib106","doi-asserted-by":"crossref","unstructured":"Armstrong A, Gooderham M, Warren R, et\u00a0al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the POETYK PSO-1 study [abstract]. In: Presented at: American Academy of Dermatology annual meeting; April 23\u201325, 2021.","DOI":"10.1136\/annrheumdis-2021-eular.1002"},{"key":"10.1016\/j.coph.2022.102292_bib107","first-page":"2020","article-title":"Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [abstract]","author":"Mease","year":"2020","journal-title":"Presented at: American College of Rheumatology Convergence"},{"key":"10.1016\/j.coph.2022.102292_bib109","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib112","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102292_bib117","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102292_bib105","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coph.2022.102292_bib108","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17a and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2022.102292_bib110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib111","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 10","key":"10.1016\/j.coph.2022.102292_bib113","article-title":"Bimekizumab maintenance of response in patients with psoriatic arthritis: 2-year results from a phase 2b dose-ranging study and its open-label extension [abstract]","volume":"72","author":"Merola","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102292_bib116","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.coph.2022.102292_bib118","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102292_bib119","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.coph.2022.102292_bib120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:56:52Z","timestamp":1761461812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222001199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":126,"alternative-id":["S1471489222001199"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102292","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102292"}}